LuvAminos
ProductsResearchLoyaltyAffiliate ProgramAboutContact us
Browse Catalog
Luvaminos

Research-grade peptides for laboratory and in-vitro research. Third-party tested, documented per batch.

(505) 460-8488

[email protected]

Shop

  • All Products

Resources

  • About
  • Research Library
  • Certificates of Analysis
  • Affiliate Program
  • Loyalty Program
  • Refer a Friend

Support

  • Contact Us
  • FAQ
  • Shipping Info
  • Returns & Refunds

Legal

  • Privacy Policy
  • Your Privacy Choices
  • Terms of Service
  • Affiliate Terms
  • Disclaimer
  • Research Use Only
Shop
  • All Products
Resources
  • About
  • Research Library
  • Certificates of Analysis
  • Affiliate Program
  • Loyalty Program
  • Refer a Friend
Support
  • Contact Us
  • FAQ
  • Shipping Info
  • Returns & Refunds
Legal
  • Privacy Policy
  • Your Privacy Choices
  • Terms of Service
  • Affiliate Terms
  • Disclaimer
  • Research Use Only

!FDA Disclaimer — Research Use Only

Statements regarding these products have not been evaluated by the U.S. Food and Drug Administration. These products are intended for laboratory and in-vitro research use only and are not for human or veterinary consumption of any kind. They are not drugs, foods, or supplements, are not FDA approved, and are not intended to diagnose, treat, cure, or prevent any disease. All products are sold exclusively to qualified researchers and must be handled by trained professionals. Read the full disclaimer →

© 2026 Luvaminos LLC. All Rights Reserved.

1209 Mountain Road PL NE STE R, Albuquerque, NM 87110

  • VisaVISA
  • Mastercard
  • American ExpressAMEX
  • DiscoverDiscover
  • Ethereum
  • SSL Secured
  • 99%+ Purity
  • Shipment Protection
Research/Cortagen

Signaling

Cortagen

A synthetic tetrapeptide (Ala-Glu-Asp-Leu) studied in non-clinical models as a short-peptide bioregulator of gene expression in bronchopulmonary and related cell systems.

Cortagen is a short, synthetic four-amino-acid peptide (sequence Ala-Glu-Asp-Leu, abbreviated AEDL) belonging to the Khavinson class of peptide bioregulators. It is studied in laboratory models of bronchial and pulmonary tissue, where investigators examine its interaction with DNA and chromatin and its association with tissue-specific gene-expression patterns.

Last reviewed June 20, 2026 · For research use only.

What is Cortagen studied for?

  • Tissue-specific gene-expression and protein-synthesis profiling in human bronchial epithelial cell cultures
  • In vitro peptide–DNA binding and DNA thermostability biophysics (UV spectrophotometry, circular dichroism, viscometry, differential scanning microcalorimetry)
  • Chromatin-conformation and histone-binding mechanistic studies
  • Rodent (nitrogen dioxide-exposure) model systems examining bronchial-epithelial morphology and secretory markers
  • Replicative-senescence / serial-passage cell-culture model systems examining differentiation-factor expression
  • Cross-kingdom short-peptide research in plant (Nicotiana tabacum) model systems

What is the molecular structure of Cortagen?

Type

Synthetic linear tetrapeptide

Molecular formula

C18H30N4O9

Molecular weight

446.45 g/mol

Amino acids

4

Sequence

Ala-Glu-Asp-Leu

Modification

Unmodified free N-/C-termini; documented in the originating patent as an acetate salt

How does Cortagen work?

Cortagen belongs to the Khavinson class of short regulatory peptides — sequences of 2–7 amino acid residues proposed to act as epigenetic modulators by penetrating cell nuclei and interacting directly with DNA and histone proteins rather than through classical receptor engagement. In vitro biophysical characterization (Morozova et al., 2017) using UV spectrophotometry, circular dichroism, and viscometry reports that AEDL forms a complex with double-stranded DNA at the guanine N7 position in the major groove without visible distortion of the double-helix structure. Differential scanning microcalorimetry work (Monaselidze et al., 2011) documents a DNA-thermostabilizing interaction with calf thymus and mouse liver DNA across a defined molar-ratio range, characterized as non-sequence-specific. Docking-based spatial modeling (Khavinson, Lin'kova & Tarnovskaya, 2016) assigns the AEDL and EDL sequences to a CTCC tetranucleotide binding motif at gene-promoter sites. Histone-binding experiments (Fedoreyeva, Vanyushin & Baranova, 2020) report AEDL interaction with linker histone H1 and core histone H3 associated with remodeling of condensed-chromatin domains. At the transcript level, AEDL is studied in human bronchial epithelial cell cultures for association with expression of differentiation factors NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2, mucin and surfactant genes MUC4, MUC5AC, and SFTPA1, and cell-cycle and signaling proteins Ki67, Mcl-1, p53, CD79, and NOS-3.

Research Focus

Studied in non-clinical molecular-biology, biophysical, and preclinical models focused on peptide–DNA interaction, chromatin regulation, and tissue-specific gene-expression in bronchopulmonary and comparative cell systems.

Peptide-bioregulator class and origin

Cortagen (Ala-Glu-Asp-Leu) is one of a family of synthetic short peptides developed within the Khavinson peptide-bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, which produced defined-sequence peptides by directed synthesis modeled on motifs identified in tissue peptide extracts. The AEDL sequence and its synthetic characterization — molecular formula C18H30N4O9; molecular weight 446.45 g/mol; documented as an acetate salt at approximately 98% HPLC peptide content — are recorded in US Patent 7,625,870 (Khavinson et al., 2009). The framework positing that short peptides of 2–7 residues may penetrate cells, enter the nucleus, and interact with DNA to associate with gene-expression changes is reviewed by Vanyushin & Khavinson (2016) and examined across the class in the systematic review by Khavinson et al. (2021). This literature originates overwhelmingly from a single research group and affiliated laboratories, and independent replication of the core DNA-interaction mechanism outside this group has not been identified.

Bronchopulmonary tissue model systems

The most sequence-specific applied work places Cortagen in bronchial and pulmonary cell and tissue models. Khavinson et al. (2014, Lung) characterized Ki67, Mcl-1, p53, CD79, and NOS-3 protein levels across serial passages of human embryonic bronchoepithelial cell cultures alongside expression profiling of bronchial-differentiation factors NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2 and mucin/surfactant genes MUC4, MUC5AC, and SFTPA1; the study also included spectrophotometric, viscometric, and circular-dichroism examination of the peptide–DNA interaction. Khavinson et al. (2012, Bulletin of Experimental Biology and Medicine) examined differentiation-factor transcripts including CXCL12 and Hoxa3 in serially passaged human bronchial epithelial cultures — used as an in vitro model of replicative senescence — applying the AEDL tetrapeptide as the tissue-matched peptide alongside non-matched short peptides as controls. In a rodent preclinical system, Kuzubova et al. (2015) used a 60-day intermittent nitrogen dioxide–exposure protocol in rats as a model of obstructive lung pathology and assessed bronchial-epithelial morphology endpoints — goblet-cell hyperplasia, squamous metaplasia, and ciliated-cell status — and secretory immunoglobulin A as a mucosal marker.

Peptide–DNA and chromatin mechanism studies

A separate strand of biophysical work characterizes AEDL–nucleic acid and AEDL–chromatin interactions in isolation. Monaselidze et al. (2011, Bulletin of Experimental Biology and Medicine) applied differential scanning microcalorimetry to measure DNA melting thermodynamics across a range of peptide-to-DNA base-pair molar ratios, examining interactions with calf thymus and mouse liver DNA. Morozova et al. (2017, Journal of Structural Chemistry) employed UV spectrophotometry, circular dichroism, and viscometry to characterize complex formation in solution at varying ionic strength and reported binding at the guanine N7 position in the major groove without visible duplex distortion. Fedoreyeva, Vanyushin & Baranova (2020, AIMS Biophysics) examined chromatin-conformation changes associated with AEDL exposure, reporting binding to linker histone H1 and core histone H3 and associated remodeling of condensed-chromatin domains. Nuclear penetration of fluorescently labeled short peptides in the Khavinson class was examined in HeLa cell cultures by Fedoreyeva et al. (2011, Biochemistry (Moscow)) as a mechanistic entry point for the proposed nucleus-targeting model. Docking-based modeling (Khavinson, Lin'kova & Tarnovskaya, 2016) associates the AEDL and EDL sequences with a CTCC promoter tetranucleotide binding site.

Comparative and cross-kingdom model systems

The proposed DNA-interaction mechanism has been examined in plant model systems as part of a broader argument for cross-kingdom conservation. Lazareva et al. (2025, International Journal of Molecular Sciences) characterized metabolism and autophagy markers — including the autophagy marker ATG8, cytochrome c release, and TUNEL-detected DNA strand breaks — in root cells of Nicotiana tabacum exposed to the AEDL tetrapeptide. An earlier study by Fedoreyeva et al. (2017, Biochemistry (Moscow)) examined AEDL alongside related short peptides for associations with expression of CLE, KNOX1, and GRF gene families in the same plant model system. These comparative studies are cited by the originating research group as supporting a conserved peptide–DNA interaction mechanism; they do not independently establish relevance in mammalian or human systems.

How is Cortagen stored & handled?

Lyophilized

−20 °C, protected from light and moisture

documented in the originating patent as a white amorphous odorless powder.

Reconstituted

2–8 °C for short-term use

avoid repeated freeze–thaw cycles.

As an unprotected tetrapeptide composed of common L-amino acids, AEDL would be expected to be susceptible to proteolytic degradation; no formal pharmacokinetic study measuring the intact peptide was identified in the verified literature.

References

Reviews

  1. 1

    Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Molecules — Systematic review — peptide regulation of gene expression across the Khavinson short-peptide class

    DOI: 10.3390/molecules26227053PubMed 34834147
  2. 2

    Khavinson VK, Lin'kova NS, Tarnovskaya SI, et al. (2016). Bulletin of Experimental Biology and Medicine — Methods/modeling review — docking models of short cell-penetrating peptides at gene-promoter sites

    DOI: 10.1007/s10517-016-3596-7
  3. 3

    Vanyushin BF, Khavinson VK (2016). Epigenetics – A Different Way of Looking at Genetics (Springer) — Book-chapter review — short peptides as epigenetic modulators of gene activity

    DOI: 10.1007/978-3-319-27186-6_5

Primary research

  1. 4

    Lazareva EM, Kazakov EP, Dilovarova TA, Kononenko NV, Fedoreyeva LI (2025). International Journal of Molecular Sciences — Primary plant-cell study — AEDL tetrapeptide effects on metabolism and autophagy markers in Nicotiana tabacum root cells

    DOI: 10.3390/ijms262211028PubMed 41303518
  2. 5

    Fedoreyeva LI, Vanyushin BF, Baranova EN (2020). AIMS Biophysics — Primary biophysical study — AEDL tetrapeptide chromatin-conformation change via histone H1/H3 binding

    DOI: 10.3934/biophy.2020001
  3. 6

    Morozova EA, Lin'kova NS, Khavinson VK, Soloviev AY, Kasyanenko NA (2017). Journal of Structural Chemistry — Primary in vitro biophysical study — AEDL tetrapeptide–DNA interaction in solution by spectrophotometry, CD, and viscometry

    DOI: 10.1134/S0022476617020299
  4. 7

    Fedoreyeva LI, Dilovarova TA, Ashapkin VV, et al. (2017). Biochemistry (Moscow) — Primary plant-gene-expression study — AEDL and related short peptides in CLE/KNOX1/GRF gene regulation in Nicotiana tabacum

    DOI: 10.1134/S0006297917040149
  5. 8

    Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. (2015). Bulletin of Experimental Biology and Medicine — Primary preclinical study — AEDL tetrapeptide in a rat nitrogen dioxide obstructive-lung model, bronchial-epithelium morphology and secretory-IgA endpoints

    DOI: 10.1007/s10517-015-3047-xPubMed 26468022
  6. 9

    Khavinson VK, Tendler SM, Vanyushin BF, et al. (2014). Lung — Primary in vitro study — AEDL tetrapeptide gene expression and protein synthesis in human bronchial epithelium

    DOI: 10.1007/s00408-014-9620-7PubMed 25015171
  7. 10

    Khavinson VK, Linkova NS, Polyakova VO, et al. (2012). Bulletin of Experimental Biology and Medicine — Primary in vitro study — tissue-specific differentiation-factor expression in serially passaged bronchial epithelial cultures

    DOI: 10.1007/s10517-012-1664-1PubMed 22808515
  8. 11

    Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF (2011). Biochemistry (Moscow) — Primary in vitro study — nuclear penetration of Khavinson-class short peptides in HeLa cells

    DOI: 10.1134/S0006297911110022PubMed 22117547
  9. 12

    Monaselidze JR, Khavinson VK, Gorgoshidze MZ, et al. (2011). Bulletin of Experimental Biology and Medicine — Primary biophysical study — AEDL tetrapeptide effect on DNA thermostability by differential scanning microcalorimetry

    DOI: 10.1007/s10517-011-1146-xPubMed 21240358
  10. 13

    Khavinson VK, Ryzhak GA, et al. (2009). US Patent 7,625,870 — Patent — synthesis and characterization of the Ala-Glu-Asp-Leu tetrapeptide for respiratory-organ research

    View source ↗
  11. 14

    Khavinson VK (2001). Bulletin of Experimental Biology and Medicine — Primary in vitro organotypic-culture study — Cortagen tissue-specific stimulation of rat brain cortex explant growth

    DOI: 10.1023/A:1013058701974PubMed 11713572
  12. 15

    Turchaninova LN, Kolosova LI, Malinin VV, Moiseeva AB, Nozdrachev AD, Khavinson VK (2000). Bulletin of Experimental Biology and Medicine — Primary preclinical study — Cortagen tetrapeptide in a rat sciatic nerve transection model, nerve conduction endpoints

    DOI: 10.1023/A:1017532001908PubMed 11276314
  13. 16

    Anisimov SV, Boheler KR, Khavinson VK, Anisimov VN (2004). Neuro Endocrinology Letters — Primary preclinical study — Cortagen tetrapeptide effect on gene expression in mouse heart by cDNA microarray

    PubMed 15159690
  14. 17

    Zarubina IV, Shabanov PD (2011). Eksperimental'naia i Klinicheskaia Farmakologiia — Primary preclinical study — Cortagen and cortexin in a rat chronic cerebral ischemia model, oxidative stress and behavioral endpoints

    PubMed 21476278
  15. 18

    Shabanov PD, Vislobokov AI (2013). Reviews on Clinical Pharmacology and Drug Therapy — Primary in vitro electrophysiology study — Cortagen tetrapeptide effects on neuronal membrane potential and spontaneous activity

    DOI: 10.17816/RCF11217-25
  16. 19

    Lezhava T, Monaselidze J, Jokhadze T, Buadze M, Gaiozishvili M (2015). International Journal of Peptide Research and Therapeutics — Primary cytogenetic study — Cortagen tetrapeptide effects on heterochromatin decondensation and ribosomal gene activation in aged-donor lymphocyte cultures

    DOI: 10.1007/s10989-014-9443-7
  17. 20

    Lezhava T, Jokhadze T, Monaselidze J, Buadze T, Gaiozishvili M, Sigua T (2020). Georgian Medical News — Primary cytogenetic study — AEDP tetrapeptide among bioregulators tested for epigenetic modification of aged heterochromatin in lymphocyte cultures

    PubMed 33526740
  18. 21

    Khavinson VK, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO (2014). Bulletin of Experimental Biology and Medicine — Primary in vitro study — short peptides and serotonin expression in aging brain cortex cell cultures

    DOI: 10.1007/s10517-014-2496-yPubMed 24909721
  19. 22

    Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V (2019). International Journal of Immunopathology and Pharmacology — Primary in vitro study — AED and related short peptides on neuronal differentiation markers in human stem cell cultures

    DOI: 10.1177/2058738419828613PubMed 30791821

Primary Database

PubChem CID 11690869↗

Research Use Only

These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.

How does Cortagen compare to related Signaling research compounds?

Molecular comparison of Cortagen and related Signaling research compounds.
CompoundTypeMolecular weightCAS number
CortagenThis pageSynthetic linear tetrapeptide446.45 g/mol—
PT-141Synthetic peptide (cyclic heptapeptide)1,025.18 g/mol189691-06-3
CardiogenSynthetic linear tetrapeptide (short peptide bioregulator)489.5 g/mol—
CerebrolysinPorcine brain-derived neuropeptide and amino-acid preparation (enzymatic hydrolysate; heterogeneous mixture)Peptide fraction <10 kDa12656-61-0
DihexaSynthetic peptidomimetic (modified tripeptide-like angiotensin IV analog)~504.66 g/mol1401708-83-5

Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.

Frequently asked questions about Cortagen

Quality & methods

  • Storage & handling →
  • How purity is measured →
  • Reading a Certificate of Analysis →